SPDR S&P Biotech

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Madrigal Pharmaceuticals Reports Q1 2026 Net Loss Widens to $94.39M Despite Strong Rezdiffra Revenue Amidst Uncertainty

Bank of America Analyst Maintains Buy Rating on Travere Therapeutics with $50 Target Price

Travere Therapeutics Completes $525 Million Convertible Note Issuance for Refinancing and Operations

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Travere Therapeutics Receives 'Modest Buy' Consensus Rating from Thirteen Analysts

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Travere Therapeutics issues convertible notes and repurchases existing convertible notes

Celldyne Announces New Data Release for MYQORZO® at the 2026 European Heart Failure Conference

Cytokinetics Announces Aficamten Superior to Metoprolol in Phase III Study

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Travere Therapeutics Insider Sells Shares, Raises Short-Term Sell Pressure Concerns

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research

SBIO

Agilent Technologies has partnered with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to enhance lipid-conjugated oligonucleotide research. This two-year collaboration aims to develop new delivery platforms for oligonucleotides, expanding therapeutic applications beyond liver tissues. The partnership combines NATi's expertise with Agilent's advanced analytical technologies, supporting the growth of the oligo therapeutics market, projected to reach $18 billion by 2030. The agreement also includes training and access to Agilent's Global Solution Development Center in Singapore.

PR Newswire

Agilent Tech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

OBIO

LABU

B. Riley Financial has lowered its price target for Orchestra BioMed (NASDAQ:OBIO) from $12.00 to $10.00 while maintaining a 'buy' rating. This new target suggests a potential upside of 148.45% from the current price. Other analysts have varied opinions, with some reaffirming 'buy' ratings and others downgrading the stock. Currently, OBIO shares are trading at $4.03, with a market cap of $241.02 million.

Market Beat

Orchestra BioMed

Direxion S&P Biotech Bull 3X

Barclays

Virtu Finc

Bank of America

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

CODX

Co-Diagnostics Inc. (CODX) has developed a Bundibugyo virus assay for rapid detection amid escalating Ebola outbreak alerts. Following WHO's emergency declaration, the company emphasizes the importance of decentralized diagnostics and rapid PCR testing. CEO Dwight Egan highlighted the need for quick mobilization in response to infectious diseases, shaped by lessons from COVID-19. The company is prepared for collaboration on future assay development. CODX shares are currently trading at $2.07, up 51.09%.

nasdaq

Co-Diagnostics

Nasdaq

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

ETON

ARKG

IBBQ

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

UCBJY

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

iShares US Medical Devices

SPDR S&P Health Equip

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

RNXT

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

Tip Ranks

RenovoRx

RenovoRx Earnings Call Signals Commercial Inflection

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

West Pharmaceutical

Arcadian Asset

S&P 500

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

VXRT

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Vaxart

Dynavax Tech

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline

Took some profit out of $T-Rex 2X Long HOOD Daily Target ETF(ROBN.US) and $SPDR S&amp;P Biotech(XBI.US) still own shares in both.Source: Sunrise Trader

T-Rex 2X Long HOOD Daily Target ETF

• Market rally hesitates due to escalating tensions in the Strait of Hormuz. • $Palantir Tech(PLTR.US)'s Q1 earnings and revenue exceeded estimates, driven by growth in its U.S. government business. • $SPDR S&amp;P Biotech(XBI.US) shows strength. • Lattice Semiconductor $Lattice Semicon(LSCC.US) and $ON Semiconductor(ON.US) Semiconductor both reported strong earnings, but ON's stock dropped. • $Grayscale Bitcoin Mini Trust ETF(BTC.US) approaches $80,000 following a compromise on the Clarity Act regarding stablecoin yields. • $Eli Lilly(LLY.US) recovered after a patient experienced liver failure from its weight-loss pill. • $Mirum Pharmaceuticals(MIRM.US) shares surged to an all-time high due to positive liver disease treatment results.

Lattice Semicon

Eli Lilly

Palantir Tech

Mirum Pharmaceuticals

ON Semiconductor

Grayscale Bitcoin Mini Trust ETF

Moving some stops to no green to red $SPDR S&amp;P Biotech(XBI.US) $CrowdStrike(CRWD.US)Source: Sunrise Trader

CrowdStrike

$SPDR S&amp;P Biotech(XBI.US) daily pullback to 50ma and bounce. A move and hold over the 10/21ma's if price wants it are next on my radar.Source: Sunrise Trader

$SPDR S&amp;P Biotech(XBI.US) my paydays sold for OK payday %. Still a day trade for now. I have swing plan ready.Source: Sunrise Trader

Don't sleep on Biotech 🧪 $SPDR S&amp;P Biotech(XBI.US)Source: TrendSpider

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

The biotech sector is really like a roller coaster ride, with XBI seeing large capital outflows and LABU leveraged ETFs plummeting... Despite all analysts saying this sector is worth watching in 2026, why is the short-term performance so disappointing? After tasting the bitterness of volatility, I finally understand making money isn't that easy. But perhaps with more patience, we might still see a turnaround. Everyone, hold tight and keep watching.

Under the pressure of interest rate cuts, small-cap stocks like $SPDR S&amp;P Biotech(XBI.US) are rising much faster than large-cap stocks like $Alphabet(GOOGL.US)😂

Alphabet

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Alphabet - C

The impact of interest rate cuts on small and mid-cap biotech stocks in the US market is immediate$Direxion S&amp;P Biotech Bull 3X(LABU.US)$SPDR S&amp;P Biotech(XBI.US)